Cargando…
Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus
INTRODUCTION: Fibroblast growth factor (FGF) 21 is an important regulator of glycemic control, but the association between circulating FGF21 and diabetic complications is poorly understood. Moreover, basal FGF21 secretion, especially in response to insulin dose, in patients with type 1 diabetes mell...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863253/ https://www.ncbi.nlm.nih.gov/pubmed/35192641 http://dx.doi.org/10.1371/journal.pone.0263774 |
_version_ | 1784655199129829376 |
---|---|
author | Taniguchi, Hirokazu Nirengi, Shinsuke Ishihara, Kengo Sakane, Naoki |
author_facet | Taniguchi, Hirokazu Nirengi, Shinsuke Ishihara, Kengo Sakane, Naoki |
author_sort | Taniguchi, Hirokazu |
collection | PubMed |
description | INTRODUCTION: Fibroblast growth factor (FGF) 21 is an important regulator of glycemic control, but the association between circulating FGF21 and diabetic complications is poorly understood. Moreover, basal FGF21 secretion, especially in response to insulin dose, in patients with type 1 diabetes mellitus (T1DM), has not been well examined. Therefore, this study aimed to determine the association of circulating FGF21 levels with diabetic complications and insulin dosage in middle-aged and elderly patients with T1DM. MATERIALS AND METHODS: A total of 127 middle-aged and elderly patients with T1DM, including 68 patients with diabetic complications, and 106 non-diabetic individuals were analyzed in this cross-sectional study. Information on demographic characteristics and T1DM was extracted from their electronic medical records. Serum FGF21 levels were determined using ELISA. RESULTS: Serum FGF21 levels were significantly lower in T1DM patients (75.2 [37.4–135.1] pg/mL) than in non-diabetic participants (151.6 [92.0–224.6] pg/mL; P < 0.001). No diabetic complications were associated with serum FGF21 concentrations. Both basal and bolus insulin doses were significantly and positively correlated with serum FGF21 levels (P < 0.05). Stepwise multiple regression analysis showed that FGF21 level was associated with age and body mass index (P < 0.05), while the basal insulin dose was an independent positive predictor of serum FGF21 levels (β = 0.197, P = 0.032). CONCLUSIONS: Circulating FGF21 levels are reduced in patients with T1DM; however, they are not associated with diabetic complications. In addition, aging, obesity, and insulin dosage are positive determinants of circulating FGF21. |
format | Online Article Text |
id | pubmed-8863253 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-88632532022-02-23 Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus Taniguchi, Hirokazu Nirengi, Shinsuke Ishihara, Kengo Sakane, Naoki PLoS One Research Article INTRODUCTION: Fibroblast growth factor (FGF) 21 is an important regulator of glycemic control, but the association between circulating FGF21 and diabetic complications is poorly understood. Moreover, basal FGF21 secretion, especially in response to insulin dose, in patients with type 1 diabetes mellitus (T1DM), has not been well examined. Therefore, this study aimed to determine the association of circulating FGF21 levels with diabetic complications and insulin dosage in middle-aged and elderly patients with T1DM. MATERIALS AND METHODS: A total of 127 middle-aged and elderly patients with T1DM, including 68 patients with diabetic complications, and 106 non-diabetic individuals were analyzed in this cross-sectional study. Information on demographic characteristics and T1DM was extracted from their electronic medical records. Serum FGF21 levels were determined using ELISA. RESULTS: Serum FGF21 levels were significantly lower in T1DM patients (75.2 [37.4–135.1] pg/mL) than in non-diabetic participants (151.6 [92.0–224.6] pg/mL; P < 0.001). No diabetic complications were associated with serum FGF21 concentrations. Both basal and bolus insulin doses were significantly and positively correlated with serum FGF21 levels (P < 0.05). Stepwise multiple regression analysis showed that FGF21 level was associated with age and body mass index (P < 0.05), while the basal insulin dose was an independent positive predictor of serum FGF21 levels (β = 0.197, P = 0.032). CONCLUSIONS: Circulating FGF21 levels are reduced in patients with T1DM; however, they are not associated with diabetic complications. In addition, aging, obesity, and insulin dosage are positive determinants of circulating FGF21. Public Library of Science 2022-02-22 /pmc/articles/PMC8863253/ /pubmed/35192641 http://dx.doi.org/10.1371/journal.pone.0263774 Text en © 2022 Taniguchi et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Taniguchi, Hirokazu Nirengi, Shinsuke Ishihara, Kengo Sakane, Naoki Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus |
title | Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus |
title_full | Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus |
title_fullStr | Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus |
title_full_unstemmed | Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus |
title_short | Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus |
title_sort | association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863253/ https://www.ncbi.nlm.nih.gov/pubmed/35192641 http://dx.doi.org/10.1371/journal.pone.0263774 |
work_keys_str_mv | AT taniguchihirokazu associationofserumfibroblastgrowthfactor21withdiabeticcomplicationsandinsulindoseinpatientswithtype1diabetesmellitus AT nirengishinsuke associationofserumfibroblastgrowthfactor21withdiabeticcomplicationsandinsulindoseinpatientswithtype1diabetesmellitus AT ishiharakengo associationofserumfibroblastgrowthfactor21withdiabeticcomplicationsandinsulindoseinpatientswithtype1diabetesmellitus AT sakanenaoki associationofserumfibroblastgrowthfactor21withdiabeticcomplicationsandinsulindoseinpatientswithtype1diabetesmellitus |